Renal neoplasms with TSC/mTOR pathway mutations - Revision history

Michael at 04:28, 20 March 2024

2024-03-20T04:28:58Z

← Older revision		Revision as of 04:28, 20 March 2024
Line 8:		Line 8:

	Mnemonic: ''REEL''.		Mnemonic: ''REEL''.

			==See also==
			*[[Everolimus]].

	==References==		==References==

Michael at 04:19, 20 March 2024

2024-03-20T04:19:18Z

← Older revision		Revision as of 04:19, 20 March 2024
Line 1:		Line 1:
	'''Renal neoplasms with TSC/mTOR pathway mutations''' is a diverse group of [[kidney tumours]].		'''Renal neoplasms with TSC/mTOR pathway mutations''' is a diverse group of [[kidney tumours]].<ref>{{cite journal \|authors=Kapur P, Brugarolas J, Trpkov K \|title=Recent Advances in Renal Tumors with TSC/mTOR Pathway Abnormalities in Patients with Tuberous Sclerosis Complex and in the Sporadic Setting \|journal=Cancers (Basel) \|volume=15 \|issue=16 \|pages= \|date=August 2023 \|pmid=37627070 \|pmc=10452688 \|doi=10.3390/cancers15164043 \|url=}}</ref>

	Kidney tumours with TSC/mTOR mutations:		Kidney tumours with TSC/mTOR mutations:
Line 7:		Line 7:
	*[[Low-grade oncocytic tumour]].<ref name=pmid35203531/>		*[[Low-grade oncocytic tumour]].<ref name=pmid35203531/>

			Mnemonic: ''REEL''.

	==References==		==References==

Michael at 04:18, 20 March 2024

2024-03-20T04:18:19Z

← Older revision		Revision as of 04:18, 20 March 2024
Line 2:		Line 2:

	Kidney tumours with TSC/mTOR mutations:		Kidney tumours with TSC/mTOR mutations:
			*[[Renal cell carcinoma with fibromyomatous stroma]].<ref name=pmid37899532>{{cite journal \|authors=Shah RB, Mehra R \|title=Renal Cell Carcinoma Associated With TSC/MTOR Genomic Alterations: An Update on its Expanding Spectrum and an Approach to Clinicopathologic Work-up \|journal=Adv Anat Pathol \|volume=31 \|issue=2 \|pages=105–117 \|date=March 2024 \|pmid=37899532 \|doi=10.1097/PAP.0000000000000419 \|url=}}</ref>
	*[[Eosinophilic solid and cystic renal cell carcinoma]].<ref name=pmid35203531>{{cite journal \|authors=Pivovarcikova K, Alaghehbandan R, Vanecek T, Ohashi R, Pitra T, Hes O \|title=TSC/mTOR Pathway Mutation Associated Eosinophilic/Oncocytic Renal Neoplasms: A Heterogeneous Group of Tumors with Distinct Morphology, Immunohistochemical Profile, and Similar Genetic Background \|journal=Biomedicines \|volume=10 \|issue=2 \|pages= \|date=January 2022 \|pmid=35203531 \|pmc=8869370 \|doi=10.3390/biomedicines10020322 \|url=}}</ref>		*[[Eosinophilic solid and cystic renal cell carcinoma]].<ref name=pmid35203531>{{cite journal \|authors=Pivovarcikova K, Alaghehbandan R, Vanecek T, Ohashi R, Pitra T, Hes O \|title=TSC/mTOR Pathway Mutation Associated Eosinophilic/Oncocytic Renal Neoplasms: A Heterogeneous Group of Tumors with Distinct Morphology, Immunohistochemical Profile, and Similar Genetic Background \|journal=Biomedicines \|volume=10 \|issue=2 \|pages= \|date=January 2022 \|pmid=35203531 \|pmc=8869370 \|doi=10.3390/biomedicines10020322 \|url=}}</ref>
	*[[Eosinophilic vacuolated tumour]].<ref name=pmid35203531/>		*[[Eosinophilic vacuolated tumour]].<ref name=pmid35203531/>
	*[[Low-grade oncocytic tumour]].<ref name=pmid35203531/>		*[[Low-grade oncocytic tumour]].<ref name=pmid35203531/>
	*[[Renal cell carcinoma with fibromyomatous stroma]].<ref name=pmid37899532>{{cite journal \|authors=Shah RB, Mehra R \|title=Renal Cell Carcinoma Associated With TSC/MTOR Genomic Alterations: An Update on its Expanding Spectrum and an Approach to Clinicopathologic Work-up \|journal=Adv Anat Pathol \|volume=31 \|issue=2 \|pages=105–117 \|date=March 2024 \|pmid=37899532 \|doi=10.1097/PAP.0000000000000419 \|url=}}</ref>

	==References==		==References==

Michael at 04:11, 20 March 2024

2024-03-20T04:11:52Z

← Older revision		Revision as of 04:11, 20 March 2024
Line 5:		Line 5:
	*[[Eosinophilic vacuolated tumour]].<ref name=pmid35203531/>		*[[Eosinophilic vacuolated tumour]].<ref name=pmid35203531/>
	*[[Low-grade oncocytic tumour]].<ref name=pmid35203531/>		*[[Low-grade oncocytic tumour]].<ref name=pmid35203531/>
			*[[Renal cell carcinoma with fibromyomatous stroma]].<ref name=pmid37899532>{{cite journal \|authors=Shah RB, Mehra R \|title=Renal Cell Carcinoma Associated With TSC/MTOR Genomic Alterations: An Update on its Expanding Spectrum and an Approach to Clinicopathologic Work-up \|journal=Adv Anat Pathol \|volume=31 \|issue=2 \|pages=105–117 \|date=March 2024 \|pmid=37899532 \|doi=10.1097/PAP.0000000000000419 \|url=}}</ref>

	==References==		==References==

Michael at 04:08, 20 March 2024

2024-03-20T04:08:17Z

← Older revision		Revision as of 04:08, 20 March 2024
Line 1:		Line 1:
	'''Renal neoplasms with TSC/mTOR mutations''' is a diverse group of [[kidney tumours]].		'''Renal neoplasms with TSC/mTOR pathway mutations''' is a diverse group of [[kidney tumours]].

	Kidney tumours with TSC/mTOR mutations:		Kidney tumours with TSC/mTOR mutations:

Michael: Michael moved page Renal neoplasms with TSC/mTOR mutations to Renal neoplasms with TSC/mTOR pathway mutations: fix title

2024-03-20T04:08:07Z

Michael moved page Renal neoplasms with TSC/mTOR mutations to Renal neoplasms with TSC/mTOR pathway mutations: fix title

← Older revision	Revision as of 04:08, 20 March 2024
(No difference)

Michael: create

2024-03-20T04:04:18Z

create

New page

'''Renal neoplasms with TSC/mTOR mutations''' is a diverse group of [[kidney tumours]].

Kidney tumours with TSC/mTOR mutations:
*[[Eosinophilic solid and cystic renal cell carcinoma]].<ref name=pmid35203531>{{cite journal |authors=Pivovarcikova K, Alaghehbandan R, Vanecek T, Ohashi R, Pitra T, Hes O |title=TSC/mTOR Pathway Mutation Associated Eosinophilic/Oncocytic Renal Neoplasms: A Heterogeneous Group of Tumors with Distinct Morphology, Immunohistochemical Profile, and Similar Genetic Background |journal=Biomedicines |volume=10 |issue=2 |pages= |date=January 2022 |pmid=35203531 |pmc=8869370 |doi=10.3390/biomedicines10020322 |url=}}</ref>
*[[Eosinophilic vacuolated tumour]].<ref name=pmid35203531/>
*[[Low-grade oncocytic tumour]].<ref name=pmid35203531/>

==References==
{{Reflist|2}}

[[Category:Genitourinary pathology]]